Neurona Therapeutics’ Progress in Phase I/II Clinical Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Ep
Neurona Therapeutics, a clinical-stage biotherapeutics company, recently announced the completion of enrollment for the first cohort in its ongoing Phase I/II clinical trial of NRTX-1001. This investigational allogeneic cell therapy is being developed to treat drug-resistant mesial temporal lobe epilepsy (MTLE). The first cohort consisted of five subjects who received a one-time dose of NRTX-1001, […]
Groundbreaking Cell Therapy NRTX-1001 Promises Over 90% Seizure Reduction: A New Hope for Drug-Resistant Epilepsy Patients
Neurona Therapeutics, a clinical-stage biotherapeutics company, has presented new data from its ongoing Phase I/II clinical trial of a one-time dose of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE). The data shows a promising reduction in seizure frequency in the first and second patients at one year and seven-months post-treatment, respectively. The […]
Revolutionary Cell Therapy Shows Promise: Over 90% Seizure Reduction in Drug-Resistant Epilepsy Patients
Neurona Therapeutics, a clinical-stage biotherapeutics company, is developing regenerative cell therapies for the treatment of neurological disorders. They recently presented updated clinical data from their ongoing Phase I/II trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE) at the American Academy of Neurology 2023 Annual Meeting. The data showed a >90% reduction […]